I would like to offer an analysis on TIGAR Health, a US-based startup focusing on transforming metabolic medicine. TIGAR Health has developed a breakthrough decision support capability for doctors treating Type 2 diabetes patients, enabling them to optimize their treatment protocol and provide personalized diabetes therapy based on analyzing a panel of biomarkers. Its proprietary algorithm, incorporating decision rules from top diabetes experts, generates a personalized TIGAR™ report to assist physicians in guiding therapy. This clinical decision support goes beyond monitoring traditional indicators like HbA1c and fasting glucose levels, addressing the underlying disease while improving glucose control. The startup anticipates significant and immediate cost savings through reduced medical events with the potential for increased savings over time through reduced complications. Furthermore, TIGAR Health's precision medicine capability is a first-of-its-kind in the field of diabetes and metabolic control, positioning them as a pioneering player in the industry. As of now, there is no information available about their last investment and investors.
Company Name: TIGAR Health
Slogan: Transforming Metabolic Medicine
Description: TIGAR Health enables doctors treating Type 2 diabetes patients to optimize their treatment protocol, providing truly personalized diabetes therapy. They have developed a breakthrough decision support capability, using an analytical reporting system based on analyzing the results from a panel of biomarkers. This is a first-of-its-kind precision medicine capability in the field of diabetes and metabolic control.
Founded: 2020
Industries: Health Care, Information Technology
Headquarter: United States
Last Investment: Not available
Last Investment Investors: Not available
Taxonomy:
Metabolic Medicine, Precision Medicine, Type 2 Diabetes, Personalized Therapy, Clinical Decision Support, Biomarkers, Diabetes Treatment, Medical Events, Cost Savings, Treatment Protocol Optimization, Patient Health, Anti-Diabetic Drugs, Healthcare Innovation
United States
